Universal CAR T-cell Hybrid CAR/PAR

About Tychon Bioscience

Tychon Bioscience is pioneering a novel approach to cancer immunotherapy with its PAR-T (Protein-Activated Receptor T-cell) platform, designed to address key shortcomings of existing cell therapies like CAR-T. The company's lead program, TYC201, is a protein-based drug that activates a patient's own T-cells to target and eliminate cancer cells, offering potential advantages in safety, manufacturing, and controllability. Tychon's pipeline focuses initially on solid tumors, an area where cell-based immunotherapies have struggled, with preclinical programs targeting EpCAM, CD133, and CD19. The company is led by a team of experienced entrepreneurs and scientists and operates as a private, pre-revenue entity advancing toward clinical trials.

Therapeutic Areas

Other Not Specified Drugs